Depo-Provera and Meningioma Risk: What Studies Show
Short answer: Several large observational studies report an association between depot medroxyprogesterone acetate (DMPA, commonly known as Depo-Provera) and meningioma, especially with prolonged exposure. The studies do not prove that the drug caused an individual tumor, and relative risk is not the same as absolute risk.
Reviewed and updated July 24, 2026.
What is a meningioma?
A meningioma is a tumor arising from the membranes surrounding the brain and spinal cord. Many are noncancerous and slow growing, but location and size can cause headaches, seizures, vision changes, weakness, or other neurological symptoms. Diagnosis relies on imaging and clinical evaluation.
Why study progestogens?
Many meningiomas express progesterone receptors, and strong associations have been reported for several high-dose progestogens. Researchers have therefore examined whether injectable medroxyprogesterone acetate is also associated with risk.
The 2024 French national study
A national case-control study published in BMJ compared women who had surgery for intracranial meningioma with matched controls. Prolonged injectable medroxyprogesterone acetate use was associated with higher odds of surgery-treated meningioma. The reported odds ratio was 5.55, but few participants had been exposed, producing uncertainty around the estimate.
The outcome was meningioma requiring surgery, not every incidental or asymptomatic tumor. Prescribing patterns in France may also differ from other countries.
Evidence published in 2025 and 2026
A comparative safety study reported increased risk after more than one year of medroxyprogesterone acetate exposure. A U.S. cohort analysis also found a greater relative risk, particularly with prolonged exposure and older age at initiation. A Swedish register study reported a similar direction of association.
A 2026 meta-analysis combined six studies and estimated a pooled odds ratio of 2.68, but statistical heterogeneity was high and the authors rated the evidence low quality. The studies do not all define exposure, duration, comparison groups, or meningioma outcomes the same way.
Relative risk versus absolute risk
A several-fold relative increase can still correspond to a small absolute risk when the baseline event is uncommon. None of the quoted odds ratios tells a specific patient her personal probability. Age, duration, prior radiation, genetics, and other factors influence baseline risk.
Association is not individual causation
Observational studies can be affected by confounding, surveillance differences, incomplete prescription records, and diagnostic timing. Consistent findings and biological plausibility strengthen concern, but they do not identify the cause of a particular tumor without a full clinical history.
What should a current or former user do?
- Do not stop contraception without arranging an effective alternative.
- Discuss duration of use, age, symptoms, and other options with the prescribing clinician.
- Seek prompt medical assessment for a new seizure, progressive neurological deficit, sudden severe headache, or acute vision change.
- Routine brain imaging for every asymptomatic former user is not established by these studies; screening decisions belong with a clinician.
Primary research
- 2024 French national case-control study
- 2025 comparative safety study
- 2025 U.S. cohort study
- 2026 systematic review and meta-analysis
This article is educational and not a diagnosis or personal contraceptive recommendation.
For additional source-grounded health-risk analysis, browse the Science archive.
Related reading: For related context, read Lamotrigine and Stevens-Johnson Syndrome: Warning Signs, Ninth Circuit Open-Carry Decisions: What They Mean, Pink Cocaine (Tusi): What It Contains and Why It Is Risky.
